GNRHR and prostate cancer: An analysis of the Surveillance, Epidemiology and End Results Medicare database which includes 73,196 patients with locoregional prostate cancer showed that the use of gonadotropin-releasing hormone receptor agonists was associated with a higher risk of coronary heart disease, sudden cardiac death, and myocardial infarction compared to orchiectomy [17, 18].